VERA_Thumbnail.jpg
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
July 01, 2024 08:00 ET | Vera Therapeutics
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
June 11, 2024 16:01 ET | Vera Therapeutics
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024 16:05 ET | Vera Therapeutics
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 4, 2024, the Compensation Committee of Vera’s Board of Directors granted...
VERA_Thumbnail.jpg
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 07, 2024 16:05 ET | Vera Therapeutics
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
May 28, 2024 08:00 ET | Vera Therapeutics
BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
ERA PR 1
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
May 25, 2024 09:40 ET | Vera Therapeutics
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater...
VERA_Thumbnail.jpg
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024 08:00 ET | Vera Therapeutics
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2...
VERA_Thumbnail.jpg
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2024 16:38 ET | Vera Therapeutics
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
April 02, 2024 08:00 ET | Vera Therapeutics
72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02,...
VERA_Thumbnail.jpg
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 20, 2024 07:30 ET | Vera Therapeutics
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and...